WO2004069176A3 - Polymer conjugates of mutated neublastin - Google Patents
Polymer conjugates of mutated neublastin Download PDFInfo
- Publication number
- WO2004069176A3 WO2004069176A3 PCT/US2004/002763 US2004002763W WO2004069176A3 WO 2004069176 A3 WO2004069176 A3 WO 2004069176A3 US 2004002763 W US2004002763 W US 2004002763W WO 2004069176 A3 WO2004069176 A3 WO 2004069176A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer conjugates
- mutated neublastin
- neublastin
- mutated
- polymer
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title abstract 3
- 101000785776 Homo sapiens Artemin Proteins 0.000 title abstract 2
- 229920000642 polymer Polymers 0.000 title abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006503213A JP4742025B2 (en) | 2003-01-31 | 2004-02-02 | Mutant neublastin polymer conjugate |
CA2514510A CA2514510C (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
EA200501212A EA008743B1 (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
MEP-438/08A MEP43808A (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
DK04707363.0T DK1594436T3 (en) | 2003-01-31 | 2004-02-02 | Polymer Conjugates of Mutated Neublastin |
KR1020127021783A KR101293805B1 (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
AU2004209966A AU2004209966B9 (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
MEP-2008-438A ME00277B (en) | 2001-02-01 | 2004-02-02 | POLYMER CONJUGATES OF MUTATED NEUBLASTlN |
BRPI0407170-0A BRPI0407170A (en) | 2003-01-31 | 2004-02-02 | mutated neoblastin polymer conjugates |
NZ541921A NZ541921A (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
YU20050585A RS52910B (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin |
DE602004028801T DE602004028801D1 (en) | 2003-01-31 | 2004-02-02 | Neublastin MUTANT |
MXPA05008168A MXPA05008168A (en) | 2003-01-31 | 2004-02-02 | Polymer conjugates of mutated neublastin. |
SI200431548T SI1594436T1 (en) | 2003-01-31 | 2004-02-02 | Mutated neublastin |
EP04707363A EP1594436B1 (en) | 2003-01-31 | 2004-02-02 | Mutated neublastin |
AT04707363T ATE478891T1 (en) | 2003-01-31 | 2004-02-02 | NEUBLASTIN MUTANTS |
IS7938A IS7938A (en) | 2003-01-31 | 2005-07-12 | Polymer synthetic neublastin mutant |
IL169945A IL169945A (en) | 2003-01-31 | 2005-07-28 | Neublastin polypeptide containing substitutions |
NO20054025A NO20054025L (en) | 2003-01-31 | 2005-08-30 | Polymer Conjugates of Mutant Neublastin. |
HK06105655.9A HK1085663A1 (en) | 2003-01-31 | 2006-05-16 | Mutated neublastin |
IL227752A IL227752A0 (en) | 2003-01-31 | 2013-08-01 | Polymer conjugates of mutated neublastin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26607101P | 2001-02-01 | 2001-02-01 | |
PCT/US2002/002319 WO2002060929A2 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
US10/356,264 US7442370B2 (en) | 2001-02-01 | 2003-01-31 | Polymer conjugates of mutated neublastin |
US10/356,264 | 2003-01-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004069176A2 WO2004069176A2 (en) | 2004-08-19 |
WO2004069176A3 true WO2004069176A3 (en) | 2007-09-20 |
Family
ID=46123760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/002763 WO2004069176A2 (en) | 2001-02-01 | 2004-02-02 | Polymer conjugates of mutated neublastin |
Country Status (3)
Country | Link |
---|---|
US (2) | US7442370B2 (en) |
ME (1) | ME00277B (en) |
WO (1) | WO2004069176A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8217146B2 (en) | 2001-03-12 | 2012-07-10 | Biogen Idec Ma Inc. | Neurotrophic factors and methods of use thereof |
US8969042B2 (en) | 2004-08-19 | 2015-03-03 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
US9138461B2 (en) | 2007-05-01 | 2015-09-22 | Biogen Ma Inc. | Compositions and methods for increasing vascularization |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
EP1572127B2 (en) | 2002-02-14 | 2014-10-29 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
WO2004045392A2 (en) | 2002-11-20 | 2004-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
JP4571776B2 (en) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | Lubricating oil composition |
NZ543365A (en) | 2003-04-18 | 2009-02-28 | Biogen Idec Inc | Polymer-conjugated glycosylated neublastin |
US7579313B2 (en) * | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
KR101215697B1 (en) | 2004-08-19 | 2012-12-28 | 바이오겐 아이덱 엠에이 인코포레이티드 | Neublastin variants |
TWI501774B (en) * | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
EP1993590B1 (en) * | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
MX2009009780A (en) * | 2007-03-16 | 2010-05-20 | Univ Leland Stanford Junior | Combination enzyme therapy for digestion of dietary gluten. |
WO2008115428A2 (en) * | 2007-03-16 | 2008-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | A scaleable manufacturing process for cysteine endoprotease b, isoform 2 |
WO2009020964A2 (en) * | 2007-08-08 | 2009-02-12 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
EA201070484A1 (en) * | 2007-11-05 | 2011-04-29 | Девелоген Акциенгезельшафт | NEW NEURTURIN CONJUGATES FOR PHARMACEUTICAL APPLICATIONS |
JP2010043063A (en) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | Diagnosis and treatment of kawasaki disease |
EP3521321B1 (en) | 2012-04-11 | 2020-11-04 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5283187A (en) * | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
DE3829752A1 (en) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | INTEGRAL ASYMMETRICAL POLYAETHERSULPHONE MEMBRANE, METHOD FOR THE PRODUCTION AND USE FOR ULTRAFILTRATION AND MICROFILTRATION |
DE3829766A1 (en) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | METHOD FOR PRODUCING MEMBRANES |
DE68925966T2 (en) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5800992A (en) * | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5084350A (en) * | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
DK0585368T3 (en) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implantable biocompatible immuno-insulating vehicle for delivery of selected therapeutic products |
CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
ES2225819T3 (en) | 1991-09-20 | 2005-03-16 | Amgen Inc. | GLIAL ORIGIN NEUROTROPHIC FACTOR. |
US5939524A (en) * | 1991-12-09 | 1999-08-17 | The Scripps Research Institute | Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use |
US5414135A (en) * | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
ATE220327T1 (en) | 1992-09-29 | 2002-07-15 | Inhale Therapeutic Syst | PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
US6472178B1 (en) | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
CA2092271C (en) * | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
EP1179350A3 (en) | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Encapsulated cell system for implantation into the human CNS |
DE4339605A1 (en) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Deodorant active ingredient combinations based on alpha, omega-alkanedicarboxylic acids and fatty acid partial glycerides |
US5834029A (en) * | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5795716A (en) * | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US5733729A (en) * | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US6063757A (en) | 1995-11-29 | 2000-05-16 | Urso; Richard G. | Wound treatment method with nerve growth factor |
EP0943690B1 (en) | 1995-12-21 | 2006-11-29 | Ajinomoto Co., Inc. | Method for refolding human activin a |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
US5754524A (en) * | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
EP0928336A1 (en) | 1996-09-26 | 1999-07-14 | Medical Research Council | Chaperone fragments |
KR100195886B1 (en) * | 1996-11-01 | 1999-06-15 | 김상조 | Pharmaceutical composition for treating diabetes mellitus |
WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
IL133974A0 (en) | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US7067473B1 (en) | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
BRPI9912819B8 (en) | 1998-07-14 | 2021-05-25 | Janssen Pharmaceutica Nv | expression vector, transgenic microorganism, uses of a nucleic acid molecule and a neurotrophic growth factor, as well as pharmaceutical compositions comprising the same |
AU778998B2 (en) * | 1998-09-22 | 2004-12-23 | University Of Maryland At Baltimore | Cystine knot growth factor mutants |
US6284540B1 (en) | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
WO2001066164A1 (en) | 1999-04-22 | 2001-09-13 | Eidgenossisch Technische Hochschule Zurich | Modified protein matrices |
PT1185648E (en) | 1999-06-22 | 2007-06-29 | Genentech Inc | Methods and compositions for inhibiting neoplastic cell growth |
EP1223966B1 (en) | 1999-10-29 | 2003-05-02 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Use of gdnf for treating corneal defects |
CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
NZ526610A (en) | 2000-12-22 | 2009-08-28 | Genentech Inc | New use of artemin, a member of the GDNF ligand family |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
UA100967C2 (en) | 2001-02-01 | 2013-02-25 | Байоджен Айдек Ма Інк. | Normal;heading 1;heading 2;heading 3;POLYMER CONJUGATES OF NEUBLASTIN AND METHODS OF USING SAME |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
WO2002078730A2 (en) | 2001-03-28 | 2002-10-10 | Biogen, Inc. | Use of neublastin polypeptides for treating neuropathic pain |
US20040077543A1 (en) | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
NZ529526A (en) | 2001-04-24 | 2006-06-30 | Purdue Research Foundation | Method and compositions for treating mammalian nerve tissue injuries |
US7135334B2 (en) | 2001-06-20 | 2006-11-14 | Genentech, Inc. | PRO20044 nucleic acids |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US7129085B2 (en) | 2001-10-11 | 2006-10-31 | Bristol-Myers Squibb Company | Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1 |
EP1314739A1 (en) | 2001-11-22 | 2003-05-28 | Bayer Ag | Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines |
GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
JP4310608B2 (en) | 2002-04-25 | 2009-08-12 | 東洋紡績株式会社 | Method of using HSP70 family protein substrate binding domain fragment |
NZ543365A (en) | 2003-04-18 | 2009-02-28 | Biogen Idec Inc | Polymer-conjugated glycosylated neublastin |
ES2323066T3 (en) | 2003-06-10 | 2009-07-06 | Nsgene A/S | IMPROVED SECRETION OF NEUBLASTIN. |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
US20050180957A1 (en) | 2004-01-16 | 2005-08-18 | Scharp David W. | Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
AU2005258101B2 (en) | 2004-06-23 | 2009-08-27 | Kolon Tissuegene, Inc. | Nerve regeneration |
US7598356B2 (en) | 2004-07-08 | 2009-10-06 | Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center | Method for purifying a protein of the cystine-knot superfamily |
GB2416539A (en) * | 2004-07-24 | 2006-02-01 | Reckitt Benckiser | Liquid cleaning composition, catalyst therefor and methods of cleaning |
KR101215697B1 (en) | 2004-08-19 | 2012-12-28 | 바이오겐 아이덱 엠에이 인코포레이티드 | Neublastin variants |
KR101241551B1 (en) | 2004-08-19 | 2013-03-11 | 바이오겐 아이덱 엠에이 인코포레이티드 | Refolding transforming growth factor beta family proteins |
WO2007042040A2 (en) | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
TWI501774B (en) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | Treatments for neurological disorders |
EP1993590B1 (en) | 2006-03-01 | 2013-12-25 | Biogen Idec MA Inc. | Compostions and methods for administering gdnf ligand family proteins |
BRPI0710800A2 (en) | 2006-04-25 | 2012-01-17 | Univ California | administration of growth factors for the treatment of snc disorders |
TWI445544B (en) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | Compositions and methods for increasing vascularization |
-
2003
- 2003-01-31 US US10/356,264 patent/US7442370B2/en not_active Expired - Fee Related
-
2004
- 2004-02-02 ME MEP-2008-438A patent/ME00277B/en unknown
- 2004-02-02 WO PCT/US2004/002763 patent/WO2004069176A2/en active Application Filing
-
2008
- 2008-06-27 US US12/163,425 patent/US8119114B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034475A2 (en) * | 1998-12-09 | 2000-06-15 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8217146B2 (en) | 2001-03-12 | 2012-07-10 | Biogen Idec Ma Inc. | Neurotrophic factors and methods of use thereof |
US8969042B2 (en) | 2004-08-19 | 2015-03-03 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
US9138461B2 (en) | 2007-05-01 | 2015-09-22 | Biogen Ma Inc. | Compositions and methods for increasing vascularization |
Also Published As
Publication number | Publication date |
---|---|
US7442370B2 (en) | 2008-10-28 |
US8119114B2 (en) | 2012-02-21 |
US20080306212A1 (en) | 2008-12-11 |
ME00277B (en) | 2011-05-10 |
US20050142098A1 (en) | 2005-06-30 |
WO2004069176A2 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004069176A3 (en) | Polymer conjugates of mutated neublastin | |
AU2002225762A1 (en) | Preparation of polymerization catalysts | |
IL227752A0 (en) | Polymer conjugates of mutated neublastin | |
AU2572499A (en) | Human hairless gene, protein and uses thereof | |
AU2002300359A1 (en) | Fusion Protein Having Enhanced in vivo Activity of Erythropoietin | |
SG149685A1 (en) | Polymer conjugates of neublastin and methods of using same | |
EP1618179A4 (en) | Polymer-conjugated glycosylated neublastin | |
AU2001268326A1 (en) | Peptides with physiological activity | |
AU2575000A (en) | Collagen-binding physiologically active polypeptide | |
AU2002230788A1 (en) | Multiplexed protein expression and activity assay | |
AU2002361889A1 (en) | Infrared sensing of concentration of methanol's aqueous solution | |
AU1620099A (en) | Ubiquitin-like conjugating protein | |
AU2067501A (en) | Human oxidoreductase proteins | |
AU2002212287A1 (en) | Catalyst support, production and use thereof in the polymerization of olefins | |
AU2001263287A1 (en) | Human protein kinase "13305" and uses therefor | |
AU4843799A (en) | Human oxidoreductase proteins | |
AU2002357666A1 (en) | 69583 and 85924, novel human protein kinase family members and uses therefor | |
AU2002344829A1 (en) | Human ugrp (uteroglobin-related protein) 1 promoter and its use | |
AU3703200A (en) | Recombinant protein c activator and uses therefor | |
AU1867999A (en) | Lysozym-analogous proteins and peptide having an anti-microbial activity, production of the same and use thereof | |
WO2002008270A3 (en) | A mort-1 interacting protein, its preparation and use | |
AU2001294741A1 (en) | 3700, a novel human protein kinase and uses therefor | |
AU5324399A (en) | Human epidermal proteins hepi-1 to hepi-6 | |
AUPR483101A0 (en) | Animal feed and compositon's and its use in raise of vitamin A,D & E in milk | |
AU2002235434A1 (en) | 15569, a novel human g protein coupled receptor and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0585 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/05707 Country of ref document: ZA Ref document number: 200505707 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2514510 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006503213 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169945 Country of ref document: IL Ref document number: 3372/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/008168 Country of ref document: MX Ref document number: 383683 Country of ref document: PL Ref document number: 1020057014050 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004209966 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 541921 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004707363 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8957 Country of ref document: GE Ref document number: 200501212 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2004209966 Country of ref document: AU Date of ref document: 20040202 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004209966 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004809133X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057014050 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004707363 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0407170 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10236 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11544 Country of ref document: GE |